504 related articles for article (PubMed ID: 15758646)
1. Molecular regulation of hepatobiliary transport systems: clinical implications for understanding and treating cholestasis.
Trauner M; Wagner M; Fickert P; Zollner G
J Clin Gastroenterol; 2005 Apr; 39(4 Suppl 2):S111-24. PubMed ID: 15758646
[TBL] [Abstract][Full Text] [Related]
2. Transcriptional regulation of hepatobiliary transport systems in health and disease: implications for a rationale approach to the treatment of intrahepatic cholestasis.
Wagner M; Trauner M
Ann Hepatol; 2005; 4(2):77-99. PubMed ID: 16010241
[TBL] [Abstract][Full Text] [Related]
3. Molecular mechanisms of cholestasis.
Zollner G; Trauner M
Wien Med Wochenschr; 2006 Jul; 156(13-14):380-5. PubMed ID: 16937039
[TBL] [Abstract][Full Text] [Related]
4. Hepatocellular transporters and cholestasis.
Pauli-Magnus C; Meier PJ
J Clin Gastroenterol; 2005 Apr; 39(4 Suppl 2):S103-10. PubMed ID: 15758645
[TBL] [Abstract][Full Text] [Related]
5. CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice.
Wagner M; Halilbasic E; Marschall HU; Zollner G; Fickert P; Langner C; Zatloukal K; Denk H; Trauner M
Hepatology; 2005 Aug; 42(2):420-30. PubMed ID: 15986414
[TBL] [Abstract][Full Text] [Related]
6. Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration.
Geier A; Wagner M; Dietrich CG; Trauner M
Biochim Biophys Acta; 2007 Mar; 1773(3):283-308. PubMed ID: 17291602
[TBL] [Abstract][Full Text] [Related]
7. Cholestatic liver diseases: slow progress in understanding and treating slowly progressive disorders.
Vleggaar FP; Van Ooteghem NA; Van Buuren HR; Van Berge Henegouwen GP
Scand J Gastroenterol Suppl; 2000; (232):86-92. PubMed ID: 11232499
[TBL] [Abstract][Full Text] [Related]
8. Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases.
Trauner M; Fickert P; Halilbasic E; Moustafa T
Wien Med Wochenschr; 2008; 158(19-20):542-8. PubMed ID: 18998069
[TBL] [Abstract][Full Text] [Related]
9. Nuclear receptors as therapeutic targets in cholestatic liver diseases.
Zollner G; Trauner M
Br J Pharmacol; 2009 Jan; 156(1):7-27. PubMed ID: 19133988
[TBL] [Abstract][Full Text] [Related]
10. Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases.
Zollner G; Fickert P; Zenz R; Fuchsbichler A; Stumptner C; Kenner L; Ferenci P; Stauber RE; Krejs GJ; Denk H; Zatloukal K; Trauner M
Hepatology; 2001 Mar; 33(3):633-46. PubMed ID: 11230744
[TBL] [Abstract][Full Text] [Related]
11. Kinetics of hepatic bile acid handling in cholestatic liver disease: effect of ursodeoxycholic acid.
Jazrawi RP; de Caestecker JS; Goggin PM; Britten AJ; Joseph AE; Maxwell JD; Northfield TC
Gastroenterology; 1994 Jan; 106(1):134-42. PubMed ID: 8276175
[TBL] [Abstract][Full Text] [Related]
12. Alisol B 23-acetate protects against ANIT-induced hepatotoxity and cholestasis, due to FXR-mediated regulation of transporters and enzymes involved in bile acid homeostasis.
Meng Q; Chen XL; Wang CY; Liu Q; Sun HJ; Sun PY; Huo XK; Liu ZH; Yao JH; Liu KX
Toxicol Appl Pharmacol; 2015 Mar; 283(3):178-86. PubMed ID: 25655198
[TBL] [Abstract][Full Text] [Related]
13. Medical treatment of cholestatic liver diseases: From pathobiology to pharmacological targets.
Paumgartner G
World J Gastroenterol; 2006 Jul; 12(28):4445-51. PubMed ID: 16874853
[TBL] [Abstract][Full Text] [Related]
14. Biliary secretion of bile acids and lipids in primary sclerosing cholangitis. Influence of cholestasis and effect of ursodeoxycholic acid treatment.
Stiehl A; Rudolph G; Sauer P; Theilmann L
J Hepatol; 1995 Sep; 23(3):283-9. PubMed ID: 8550992
[TBL] [Abstract][Full Text] [Related]
15. Nuclear hormone receptor-dependent regulation of hepatic transporters and their role in the adaptive response in cholestasis.
Stahl S; Davies MR; Cook DI; Graham MJ
Xenobiotica; 2008 Jul; 38(7-8):725-77. PubMed ID: 18668429
[TBL] [Abstract][Full Text] [Related]
16. [New molecular features of cholestatic diseases of the liver].
Méndez-Sánchez N; Chavez-Tapia NC; Uribe M
Rev Invest Clin; 2003; 55(5):546-56. PubMed ID: 14968476
[TBL] [Abstract][Full Text] [Related]
17. Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations.
Zollner G; Marschall HU; Wagner M; Trauner M
Mol Pharm; 2006; 3(3):231-51. PubMed ID: 16749856
[TBL] [Abstract][Full Text] [Related]
18. Pathophysiology and Diseases of the Proximal Pathways of the Biliary System.
Nakanishi Y; Saxena R
Arch Pathol Lab Med; 2015 Jul; 139(7):858-66. PubMed ID: 26125426
[TBL] [Abstract][Full Text] [Related]
19. Failure of ursodeoxycholic acid to prevent a cholestatic episode in a patient with benign recurrent intrahepatic cholestasis: a study of bile acid metabolism.
Crosignani A; Podda M; Bertolini E; Battezzati PM; Zuin M; Setchell KD
Hepatology; 1991 Jun; 13(6):1076-83. PubMed ID: 2050325
[TBL] [Abstract][Full Text] [Related]
20. Cytoprotection with ursodeoxycholic acid: effect in chronic non-cholestatic and chronic cholestatic liver disease.
Lirussi F; Okolicsanyi L
Ital J Gastroenterol; 1992 Jan; 24(1):31-5. PubMed ID: 1571577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
